The claim limitation that matters in US20260199086A1 is not a structure at all. Edwards Lifesciences Corporation's application, titled PROSTHETIC HEART VALVES AND METHODS FOR SUPRA-ANNULAR IMPLANTATION and published on July 16, 2026, opens with a method claim, and the four active steps it recites are entirely conventional transcatheter practice: insert a delivery apparatus carrying the valve in a radially compressed state into the patient's vasculature; advance it until the compressed valve is within the aortic root; align it relative to one or more anatomical features of the aortic root; and radially expand it. Nothing in those steps distinguishes the claim from routine transcatheter aortic valve replacement. The distinguishing work is done by the closing wherein clause, which is a limitation on the outcome rather than on the technique.

That clause requires the expanded frame to occupy a specific anatomical window, defined by two landmarks interventional cardiologists already measure routinely. Attached to the expansion step, the position is not an optional consequence of the method but a condition it must satisfy to fall within the claim.

wherein an inflow end of a frame of the radially expanded prosthetic heart valve is above an annulus of an aortic valve and an outflow end of the frame of the radially expanded prosthetic heart valve is below a sinotubular junction (STJ) of the aortic root.— PROSTHETIC HEART VALVES AND METHODS FOR SUPRA-ANNULAR IMPLANTATION, US20260199086A1

The dependent claims supply the geometry that makes such a landing possible. Claim 8 recites the precondition directly, requiring that a height of the frame of the prosthetic heart valve is less than a distance between the annulus and the STJ — a device constraint expressed inside a method claim, which is a familiar drafting move when the inventive contribution sits at the seam between hardware and technique. Claim 9 then narrows that height to a range of 15.5 mm to 22.5 mm, converting an anatomical relationship into a manufacturable size band. A frame that must clear the annulus at one end and stop short of the STJ at the other has only the intervening distance to work with.

Three independent methods, three different framings of the same window

The application does not rely on a single independent claim. Claim 14 is a second independent method that reorders the same idea into a selection procedure: it begins by determining a distance between an annulus and an STJ of an aortic root of the patient, then selecting a prosthetic heart valve that has a height in a radially expanded state that is less than the distance between the annulus and the STJ, before the insertion, advancement and expansion steps follow. Where claim 1 states the positional outcome as a wherein condition, claim 14 front-loads it as a sizing decision made before the catheter is introduced. Claim 16 carries the same 15.5 mm to 22.5 mm band into that second family. The practical difference in scope is one of who performs the distinguishing act — claim 14 reads on the measurement-and-selection workflow, claim 1 on the implantation itself.

Claim 17 is a third independent method, stripped to a single active step. It recites only radially expanding the prosthetic heart valve from a radially compressed state to a radially expanded state within an aortic root, together with the same positional wherein clause expressed in anatomical terms: inflow end above the annulus, outflow end below the sinotubular junction. Dropping the insertion and advancement steps removes the delivery-system context entirely, so claim 17 is directed at the expansion event and its result rather than at a full catheterization sequence.

The claim set is notable for using two different directional vocabularies across the claims that depend from claim 17. Claim 18 and claim 20 do not use the anatomical above-and-below language of claim 17. Instead, both recite that the frame — claim 18 — or the entirety of the prosthetic heart valve — claim 20 — is within the aortic root upstream of the annulus of the aortic valve and downstream of the STJ after radial expansion. That is flow-direction vocabulary rather than anatomical vocabulary, and in aortic flow, where blood travels from the annulus toward the sinotubular junction, the two sets of terms describe the window from opposite reference points. Both formulations appear in the application as published. Which one governs, and whether the difference is substantive or a drafting artifact, is a question for prosecution and for any claim construction that follows; it is not resolved on the face of the publication.

Claims 2 and 3 require a related reading discipline. Claim 2 recites positioning the inflow end of the frame below the annulus, and claim 3 recites positioning the outflow end above the STJ. Both are directed to the aligning step, which occurs while the valve is still radially compressed, during alignment — not to the deployed state that claim 1's wherein clause governs. The application therefore describes a two-stage sequence in which the compressed device is straddled across the landmarks for orientation and then expands into the narrower window between them. Read out of that staging context, claims 2 and 3 would appear to invert claim 1; read within it, they describe the intermediate position from which the claimed final position is reached.

Claims 10 through 13 add retention hardware to the claim-1 family. Claim 10 recites deploying one or more anti-migration features generally; claim 11 narrows that to deploying one or more frame anchors over a native leaflet free edge; claim 12 recites engaging an annular flange of an outer skirt with native tissue above the annulus; and claim 13 recites an ingrowth-resistant annular extension that extends into the annulus in the expanded state. These are the claims that respond to the obvious consequence of the positional limitation: a frame that does not seat across the annulus forgoes the radial-friction anchoring that annular seating provides, so the application recites alternative fixation at the leaflets and at supra-annular tissue instead. The abstract, as background description, frames the whole disclosure in those terms, describing prosthetic valves, delivery apparatus and methods for preventing or limiting migration of an implanted prosthetic valve.

Classification and portfolio position

The application is classified under CPC A61F 2/2418 and A61F 2/2436, the subgroups covering prosthetic heart valves of the self-expanding and delivery-related varieties, with A61F 2220/0008 as an indexing code. That places it in the densest neighborhood of the transcatheter valve landscape, and the classification is consistent with a filing whose novelty is asserted at the level of implantation position and frame height rather than leaflet chemistry. Named inventors are Nikolai Gurovich and Tamir S. Levi.

The filing sits within an active recent publication run assigned to Edwards Lifesciences Corporation. The nearest sibling on an axial-positioning reading is US20260137510A1, directed to prosthetic valves and delivery assemblies with positioning arms, which addresses where the device comes to rest by a different mechanism. US20260191639A1, on a sealing member for a prosthetic heart valve, pairs with the outer-skirt and annular-flange limitation of claim 12. US20260183104A1 and US20260183105A1 cover the valve itself and leaflet attachment within a frame. US20260174553A1 is directed to polymeric tissue-adherent leaflet surfaces, US20260137514A1 to a thromboresistant skirt portion, and US20260151596A1 to a hybrid expandable sheath.

One point governs how all of the above should be read: US20260199086A1 is an A1 publication, meaning a pending application made public at the statutory eighteen-month mark. No claim in it has been examined to allowance, and the claim set discussed here is the set as filed and published, not as it may issue. Applications routinely emerge from prosecution with narrowed limitations, consolidated independent claims, or resolved terminology. What the publication establishes today is the scope Edwards Lifesciences has asked for: implantation methods defined by landing an entire valve frame in the space between the aortic annulus and the sinotubular junction.